πŸ‡ΊπŸ‡Έ FDA
Patent

US 9475875

Anti-EGFRvIII antibodies and uses thereof

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 9475875 (Anti-EGFRvIII antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K39/3955, A61K39/39558